NR565_week_2_.docx.pdf| Full Q&A | 2026/2027
a. Describe your assigned client’s situation. Why are they presenting to the clinic? What
medications are they currently taking?
a. Tyrone Ball presents to the clinic for a follow-up after receiving a PCI with stent
placement x2 for a STEMI. The medications he is currently taking are atorvastatin
(Lipitor) 40mg daily and diltiazem (Cardizem) 120mg BID.
b. Assess the applicable clinical practice guideline (CPG) for your assigned client linked on
the same page in the lesson where the client case is located. What treatment is
recommended by the CPG for your client’s situation?
a. Treatment recommendations by the CPG are appropriate for patients with CCD
treated with percutaneous coronary intervention (PCI) and a drug-eluting stent,
need to complete a course of dual antiplatelet therapy (DAPT), P2Y12 inhibitor
monotherapy for at least 12 months to reduce bleeding risk (Virani et al., 2023).
c. Discuss your personal professional assessment of the client’s situation provided in the
scenario. What pharmacological treatment is necessary and why?
a. Tyrone recently suffered from a STEMI; he underwent a PCI with stent placement
x2. Patient is stable with vital signs of BP: 121/69 and HR: 87. His labs showed
that his cholesterol is well controlled. The PCI insertion site on his right groin has
no bleeding or hematoma. His medications will stay the same due to well-
controlled cholesterol and blood pressure. New medication treatment will be
implemented according to the recommendation by the CPG, which includes a
DAPT and a P2Y12 inhibitor (Virani et al., 2023). The most common DAPT is
aspirin, but due to Tyrone’s allergy to aspirin, the P2Y12 inhibitor clopidogrel
will be prescribed.
d. Reflect on additional questions about your assigned client that may influence treatment.
What else do you need to know? What follow-up assessments, labs, or conversations are
required to ensure optimal health outcomes?
a. Tyrone will need to be educated on the side effects of clopidogrel, which is an
increased risk of bleeding. He is at a higher risk of bleeding due to his history of a
TIA and hypertension. It is important that he adheres to his medication regimen
and takes clopidogrel as prescribed, and does not stop abruptly, leading to
increased risk of clots forming inside the stent (American Heart Association, Inc.,
2023). Education on his adherence to controlling his blood pressure, high
cholesterol, smoking cessation, physical activity, and a healthy diet will ensure
Tyrone’s optimal health outcome.
.
References
American Heart Association, Inc. (2023). Treatments +
tests. https://www.heart.org/-/media/files/health-topics/answers-by-heart/what-is-dapt.pdf
Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D.
L., Fearon, W. F., Hess, B., Johnson, H. M., Kazi, D. S., Kolte, D., Kumbhani, D. J., LoFaso, J.,
Mahtta, D., Mark, D. B., Minissian, M., Navar, A. M., Patel, A. R., . . . Williams, M. S. (2023).
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients with
This study source was downloaded by 1827175 from cliffsnotes.com on 01-08-2026 20:13:57 GMT -06:00
https://www.cliffsnotes.com//study-notes/24981923
a. Describe your assigned client’s situation. Why are they presenting to the clinic? What
medications are they currently taking?
a. Tyrone Ball presents to the clinic for a follow-up after receiving a PCI with stent
placement x2 for a STEMI. The medications he is currently taking are atorvastatin
(Lipitor) 40mg daily and diltiazem (Cardizem) 120mg BID.
b. Assess the applicable clinical practice guideline (CPG) for your assigned client linked on
the same page in the lesson where the client case is located. What treatment is
recommended by the CPG for your client’s situation?
a. Treatment recommendations by the CPG are appropriate for patients with CCD
treated with percutaneous coronary intervention (PCI) and a drug-eluting stent,
need to complete a course of dual antiplatelet therapy (DAPT), P2Y12 inhibitor
monotherapy for at least 12 months to reduce bleeding risk (Virani et al., 2023).
c. Discuss your personal professional assessment of the client’s situation provided in the
scenario. What pharmacological treatment is necessary and why?
a. Tyrone recently suffered from a STEMI; he underwent a PCI with stent placement
x2. Patient is stable with vital signs of BP: 121/69 and HR: 87. His labs showed
that his cholesterol is well controlled. The PCI insertion site on his right groin has
no bleeding or hematoma. His medications will stay the same due to well-
controlled cholesterol and blood pressure. New medication treatment will be
implemented according to the recommendation by the CPG, which includes a
DAPT and a P2Y12 inhibitor (Virani et al., 2023). The most common DAPT is
aspirin, but due to Tyrone’s allergy to aspirin, the P2Y12 inhibitor clopidogrel
will be prescribed.
d. Reflect on additional questions about your assigned client that may influence treatment.
What else do you need to know? What follow-up assessments, labs, or conversations are
required to ensure optimal health outcomes?
a. Tyrone will need to be educated on the side effects of clopidogrel, which is an
increased risk of bleeding. He is at a higher risk of bleeding due to his history of a
TIA and hypertension. It is important that he adheres to his medication regimen
and takes clopidogrel as prescribed, and does not stop abruptly, leading to
increased risk of clots forming inside the stent (American Heart Association, Inc.,
2023). Education on his adherence to controlling his blood pressure, high
cholesterol, smoking cessation, physical activity, and a healthy diet will ensure
Tyrone’s optimal health outcome.
.
References
American Heart Association, Inc. (2023). Treatments +
tests. https://www.heart.org/-/media/files/health-topics/answers-by-heart/what-is-dapt.pdf
Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D.
L., Fearon, W. F., Hess, B., Johnson, H. M., Kazi, D. S., Kolte, D., Kumbhani, D. J., LoFaso, J.,
Mahtta, D., Mark, D. B., Minissian, M., Navar, A. M., Patel, A. R., . . . Williams, M. S. (2023).
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients with
This study source was downloaded by 1827175 from cliffsnotes.com on 01-08-2026 20:13:57 GMT -06:00
https://www.cliffsnotes.com//study-notes/24981923
